Tabarroki, Ali <br/><br/>
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.  [electronic resource] 

 -  Leukemia & lymphoma  Feb 2015 
 - 497-9 p.  digital 
<br/><br/> Publication Type: Case Reports; Letter 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2014.916805  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Azacitidine--administration & dosage<br/>DNA Modification Methylases--antagonists & inhibitors<br/>Decitabine<br/>Fatigue--prevention & control<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Middle Aged<br/>Nitriles<br/>Primary Myelofibrosis--drug therapy<br/>Pyrazoles--administration & dosage<br/>Pyrimidines<br/>Remission Induction<br/>Treatment Outcome